Profile
Katja Rosenkranz is currently the Director at dualyx NV since 2020 and a Partner at V-Bio Ventures BV since 2016.
Previously, she worked as the Director-Executive Board at Clearstream Banking AG from 2009 to 2012.
She also held positions as Director at AgomAb Therapeutics NV and COO, CFO & Head-Administration at Advitos GmbH from 2009 to 2012.
Katja Rosenkranz active positions
| Companies | Position | Start |
|---|---|---|
V-Bio Ventures BV
V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures invests in companies located in Europe and beyond. The firm focuses on sectors such as therapeutics, including both drug discovery and drug development. It participates in early stage capital requirements. | Private Equity Investor | 2015-12-31 |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Develops differentiated biologicals for autoimmune diseases | Director/Board Member | 2020-05-30 |
Former positions of Katja Rosenkranz
| Companies | Position | End |
|---|---|---|
Clearstream Banking AG
Clearstream Banking AG Regional BanksFinance Provides commercial banking services | Corporate Officer/Principal | 2012-03-30 |
| AGOMAB THERAPEUTICS NV | Director/Board Member | - |
Advitos GmbH
Advitos GmbH Medical SpecialtiesHealth Technology Develops and commercializes liver support therapy devices | Director of Finance/CFO | 2012-06-13 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Clearstream Banking AG
Clearstream Banking AG Regional BanksFinance Provides commercial banking services | Finance |
Advitos GmbH
Advitos GmbH Medical SpecialtiesHealth Technology Develops and commercializes liver support therapy devices | Health Technology |
V-Bio Ventures BV
V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures invests in companies located in Europe and beyond. The firm focuses on sectors such as therapeutics, including both drug discovery and drug development. It participates in early stage capital requirements. | Finance |
AgomAb Therapeutics NV
AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Develops differentiated biologicals for autoimmune diseases | Commercial Services |
- Stock Market
- Insiders
- Katja Rosenkranz
















